JMJocelyn Moyes

Jocelyn Moyes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jocelyn Moyes has a total of 152 co-authors. Here are the top co-authors by number of shared publications:

  • Cheryl Cohen

    Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    26 shared publications
  • Stefano Tempia

    Partnership for International Vaccine Initiative, Task Force for Global Health, Atlanta, GA

    15 shared publications
  • Anne von Gottberg

    Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service , Johannesburg

    13 shared publications
  • Sibongile Walaza

    Centre for Respiratory Diseases and Meningitis National Institute for Communicable Diseases of the National Health Laboratory Service Johannesburg South Africa

    12 shared publications
  • Nicole Wolter

    Centre for Respiratory Diseases and Meningitis National Institute for Communicable Diseases of the National Health Laboratory Service Johannesburg South Africa

    11 shared publications
  • Nicole Wolter

    Centre for Respiratory Diseases and Meningitis National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service Johannesburg South Africa

    10 shared publications

Latest Publications

  • Open Access

    Respiratory Syncytial Virus Symptomatic Fraction, Shedding and Detection in Children Aged 6–23 Months in South Africa in 2022

    by Cheryl Cohen, Mignon du Plessis, Neil Martinson, Jocelyn Moyes, Sibongile Walaza, Nicole Wolter, Mvuyo Makhasi, Fahima Moosa, Myrna Charles, Aaron M. Samuels, et al.

    Background: Accurate detection of RSV infections is important to understand epidemiology. We estimated symptomatic fraction and shedding duration of reverse‐transcription polymerase chain reaction (RT‐PCR)‐confirmed cases and compared RSV detection through molecular and serologic techniques. Methods: We enrolled healthy children aged 6–23 months in a prospective cohort study, from May to October 2022, collecting thrice‐weekly mid‐turbinate nasal swabs for RSV RT‐PCR testing. We collected serum at baseline and end of follow‐up and detected anti‐RSV IgG using enzyme‐linked immunosorbent assay (ELISA) and multipathogen bead‐based immunoassay (MIA). We ascertained symptoms by twice‐weekly nurse visits, and daily caregiver symptom diaries. We calculated sensitivity, specificity, and positive (PPV) and negative (NPV) predictive value of RT‐PCR, ELISA, and MIA compared to a standard (two or more assays‐positive) among children with paired sera and baseline blood preceding an RT‐PCR–confirmed episode. Results: The RSV season started mid‐February 2022. We enrolled 93 participants; 87 (94%) followed to the final study visit. Forty individuals had one or more RT‐PCR–confirmed RSV infection, and six of them had a repeat episode. One‐or‐more symptom was reported from 54% (25/46) of RT‐PCR–confirmed episodes, fever in 26% (12/46), and cough in 37% (17/46). Median RNA shedding duration was 7 days (IQR = 4–11 days). Among 80 children meeting criteria, ELISA and MIA each had > 92% sensitivity, specificity, PPV, and NPV while RT‐PCR had 78% (95% CI = 61%–90%) sensitivity, 98% (95% CI = 88–100%) specificity, 97% (95% CI = 82%–100%) PPV, and 84% (95% CI = 71%–93%) NPV. Discussion: Approximately half of RSV episodes were symptomatic. Serology had a high sensitivity and specificity for infection identification.

  • Open Access

    The clinical and chest radiographic features of respiratory syncy- tial virus-associated severe respiratory illness in hospitalised adults in South Africa, 2022 - 2023

    by N Goolam, J Naude, K Bishop, M Zunza, E Irusen, J Moyes, C Cohen, S Walaza, A Parker

    Background. In most healthy adults, respiratory syncytial virus (RSV) causes mild self-limiting respiratory infection. However, vulnerable populations may present differently or have more complicated courses of disease. Objectives. To describe the clinical and radiographic features of adults hospitalised with RSV-associated severe respiratory illness (SRI) in two urban hospitals during 2022 and 2023. Methods. Patients aged ≥18 years were enrolled through systematic sentinel surveillance for SRI. Clinical characteristics and radiographic profiles of RSV-infected adults were reviewed. Results. Eighteen (2%) of 916 enrolled hospitalised patients with SRI tested positive for RSV at the two hospitals. Other pathogens detected included SARS-CoV-2 (n=69/916; 8%), influenza (n=49/916; 5%) and pertussis (n=10/916; 1%). The median (range) age was 50 (35 - 75) years, and 12 (67%) were female. All had at least one comorbidity, including immunocompromising conditions (n=15/18; 83%), metabolic conditions (n=8/18; 44%), structural lung disease (n=12/18; 66%) and cardiovascular conditions (n=3/18; 16%). Among persons living with HIV (n=11/18; 61%), 72% (n=8/11) had suppressed HIV viral loads, and 9/11 (81%) had CD4 counts <250 cells/μL. Median (range) length of hospital stay was 4.5 (1 - 15) days. All patients received empirical antibiotics, intravenously in 12/18 (66%); only 5/12 (41%) de-escalated to oral antibiotics. Radiographic findings demonstrated post-tuberculosis lung disease (PTLD) in 50% of patients (n=9/18), of whom 11 (61%) had new ground-glass opacifications, with lobar v. diffuse in 55% (n=6/11) v. 45% (n=5/11). Conclusion. The high prevalence of underlying conditions in adults with RSV-associated SRI, specifically HIV and PTLD, suggests that targeted vaccination in these groups may prevent hospitalisation with RSV-associated SRI.


  • Open Access

    Aetiological Fraction of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens in Infants Aged < 1 Year Hospitalised With Respiratory and Non‐Respiratory Medical Illness in South Africa, 2016–2018

    by Nicole Wolter, Cheryl Cohen, Anne von Gottberg, Stefano Tempia, Jocelyn Moyes, Claire von Mollendorf, Florette K. Treurnicht, Orienka Hellferscee, Kathleen Subramoney, Malefu Moleleki, et al.

    Background: Understanding the contribution of pathogens to respiratory illness in infants is important to guide interventions. We assessed the aetiology of respiratory pathogens among infants hospitalised with respiratory and non‐respiratory illness.Methods: We conducted an unmatched case–control study among infants aged < 1 year. Cases were admitted with acute respiratory and non‐respiratory illness in November 2016–October 2018. Controls were infants presenting for immunisation with no reported illness. Nasopharyngeal aspirates and blood were tested using multi‐pathogen real‐time PCR. Aetiological fraction (AF) was calculated using logistic regression, adjusting for HIV, age, season and pathogens with higher prevalence in cases than controls. Factors associated with respiratory illness hospitalisation were assessed using logistic regression.Results: Overall, 1214 cases (846 respiratory, 368 non‐respiratory) and 684 controls were included. Respiratory syncytial virus (RSV) (AF 94.0%), influenza (AF 72.6%) and human metapneumovirus (HMPV) (AF 74.9%) were significantly attributable to respiratory illness hospitalisation. Klebsiella pneumoniae had significant AF in both respiratory (AF 48.0%) and non‐respiratory (AF 60.7%) hospitalisation. HIV exposure (adjusted odds ratio [aOR] 1.5, 95% confidence interval [CI] 1.1–2.0) and living with HIV (aOR 6.6, 95%CI 2.1–20.5), underlying illness (aOR 4.8, 95%CI 1.3–17.6), malnutrition (aOR 6.0, 95%CI 4.0–8.9), infection with RSV (aOR 19.7, 95%CI 11.4–34.1), influenza (aOR 5.7, 95%CI 2.3–14.1) or HMPV (aOR 4.1, 95%CI 2.0–8.6) were associated with respiratory illness hospitalisation.Conclusions: Maternal immunisation to prevent severe RSV and influenza illness in infants should be prioritised. In addition, improved infant nutrition and the prevention of HIV‐infection and HIV‐exposure could reduce the high burden of severe respiratory illness.


  • Open Access

    The roles of pre-season immunity, age, viral shedding, and community exposures in shaping influenza household transmission dynamics

    by Molly K Sauter, Jackie Kleynhans, Jocelyn Moyes, Meredith L McMorrow, Florette K Treurnicht, Orienka Hellferscee, Anne von Gottberg, Nicole Wolter, Amelia Buys, Lorens Maake, et al.

    Our understanding of influenza transmission remains imperfect due to the high prevalence of asymptomatic infections that often go undetected. To address this challenge, we leveraged uniquely resolved data from a household cohort study spanning three consecutive years in rural and urban South Africa. The study incorporated pre-season serum collection and twice-weekly virological testing during the influenza season, regardless of symptom presence. We developed a subtype/lineage-specific influenza household transmission model that accounts for time-resolved viral shedding across the full clinical spectrum of infections, allowing us to disentangle the role of household and community exposures, pre-season immunity, and age on transmission. Our analysis revealed that viral shedding intensity, as measured by the cycle threshold (Ct) values of infected household members, significantly correlated with the risk of transmission for all four influenza subtypes/lineages. After adjusting for viral shedding, pre-season hemagglutination inhibition (HAI) titers greater than 1:40 were associated with a significantly lower risk of infection acquisition for A(H1N1)pdm09, A(H3N2), and B/Victoria, but not for B/Yamagata. Notably, children exhibited higher susceptibility and longer viral shedding durations compared to adults across all subtypes/lineages, even after adjusting for pre-season HAI titers. While our findings support that HAI titers correlate with protection, the strong residual effects of age on susceptibility and viral shedding may reflect the accumulation of additional immune responses shaped by repeated exposures over time. Our study underscores the need to explore immune mechanisms beyond HAI titers that modulate influenza susceptibility and transmission.


  • Open Access

    Home‐Based Testing as an Approach to Estimate Influenza Vaccine Effectiveness in South Africa, 2021–2022—A Pilot Study

    by Jocelyn Moyes, Mvuyo Makhazi, Sibongile Walaza, Phiwokuhle Ntombela, Fahima Moosa, Anne von Gottberg, Nicole Wolter, Mignon du Plessis, Gillian Hunt, Cherie Cawood, et al.

    Background: Surveillance programmes for influenza and other respiratory pathogens are important to generate vaccine effectiveness (VE) estimates and to inform vaccine composition. We aimed to explore the feasibility and acceptability of home‐based testing.Methods: In three out of nine provinces in South Africa, we established a self‐referral system for individuals aged ≥ 18 years with respiratory symptoms of ≤ 10 days duration. Following consent, swab collection material was delivered to participants who also completed a questionnaire including self‐reported vaccination status. Swabs were tested by PCR for influenza, respiratory syncytial virus (RSV) and SARS‐CoV‐2. A test‐negative methodology was used to estimate influenza VE.Results: Of 1456 samples collected between 19 November 2021 and 3 September 2022, 73 (5%) tested positive for influenza, 38 (3%) tested positive for RSV and 394 (27%) for SARS‐CoV‐2. We subtyped 55% (40/73) of the influenza positive specimens; 16/40 (40%) were influenza A(H1N1)pdm09; 10/40 (25%)A(H3N2)) and all 14/40(35%) influenza B were B/Victoria. Only 20% (279/1451) of participants reported influenza‐like illness case definition symptoms of fever and cough. Influenza vaccine coverage was 11% (157/1454). The overall influenza VE was 26% (95% confidence interval: −73%, 69%). Of the completed acceptability questionnaires, 123/127 (97%) participants would make use of the service again; 90% (1306) were recruited via the COVID‐19 testing centre (call in, social media, webpage), and 7% (99/1306) through CoughWatchSA.Conclusions: Home‐based swabbing was feasible and acceptable. We were able to calculate an influenza VE, although a larger sample size and verification of vaccine status may improve the VE estimates in the future.


  • Open Access

    A Potential Platform for Future Vaccine Trials Identifies a High Incidence of Symptomatic and Asymptomatic Influenza Infection Among Children Aged 6 to 23 Months in South Africa

    by Cheryl Cohen, Mignon du Plessis, Neil Martinson, Jocelyn Moyes, Sibongile Walaza, Nicole Wolter, Mvuyo Makhasi, Fahima Moosa, Myrna Charles, Aaron M Samuels, et al.

    Background: Approaches for determining whether influenza vaccination prevents infection, attenuates illness, or both are important for developing improved vaccines. We estimated influenza infection incidence and evaluated symptom ascertainment methodologies in children to inform future vaccine trial design. Methods: We conducted a prospective cohort study among children aged 6 to 23 months from May to October 2022. Study nurses collected symptom and temperature data and midturbinate nasal swabs twice weekly irrespective of symptoms; caregivers entered symptom data daily and collected nasal swabs weekly. Samples were tested for influenza with polymerase chain reaction. Results: Of 230 healthy screened children, 93 were enrolled, of whom 87 (94%) completed 6-month follow-up. In total, 95% (4245/4476) of scheduled nurses, 90% (2045/2276) of caregiver swabs, 99% (92/93) of baseline blood collections, and 67% (9245/13 768) of scheduled symptom diaries were completed. Polymerase chain reaction–confirmed influenza incidence was 65% (60/93) for ≥1 infection; 11 (18%) individuals had 2 episodes and 1 (2%) had 3. Of 73 episodes, 55 (75%) had ≥1 symptom and 37 (51%) had fever (measured and/or reported). Median infection duration was 7 days (IQR, 4–9). Human RNase P gene was detected in 99% (2032/2045) of caregiver-collected swabs, through which 5 additional episodes were identified. Per episode, caregivers' diaries of reported and measured fever were 19% (25/73, 34%) and 11% (15/73, 21%) higher than nurse-reported (11/73, 15%) and nurse-measured (7/73, 10%) fever, respectively. Conclusions: The incidence of influenza infection was high and mainly symptomatic, suggesting that this platform could be suitable for future trials of vaccine efficacy and correlates of protection against infection and illness in children.


  • Open Access

    Risk factors for severe respiratory syncytial virus-associated respiratory tract infection in a high HIV prevalence setting, South Africa, 2012 – 2018

    by Jocelyn Moyes, Stefano Tempia, Sibongile Walaza, Adam L. Cohen, Florette Treurnicht, Orienka Hellferscee, Nicole Wolter, Anne von Gottberg, Halima Dawood, Ebrahim Variava, et al.

    Identifying risk factors for respiratory syncytial virus (RSV)–associated severe acute respiratory illness (SARI) will assist with targeting vaccine interventions. Using surveillance data from South Africa (2012–2018), we compared the characteristics of individuals with RSV-associated influenza-like illness (ILI) (reference group) to those with RSV-associated SARI to describe factors associated with SARI using a multivariable analysis. RSV was detected in 6% (483/7792) of ILI cases and 15% (844/5672) of SARI cases. Factors associated with SARI in children included age < 2 months, compared to age 2–4 years (adjusted odds ratio (aOR) 54.4; 95% confidence interval (CI) 23.5–125.8), malnutrition (aOR 1.9; 95% CI 1.2–3.2), prematurity (aOR 2.4; 95% CI 1.3–4.6) and living with HIV (LWH) (aOR 22.5; 95% CI 2.9–174.3). In individuals ≥ 5 years, factors associated with SARI included age ≥ 65 years compared to age 5–24 years (aOR 10.7; 95% CI 1.1–107.5), symptom duration ≥ 5 days (aOR 2.7; 95% CI 1.1–6.3), underlying illness (aOR 2.7; 95% CI 1.5–26.1) and LWH (aOR 16.8, 95% CI: 4.8–58.2). Individuals at the extremes of age and those with identified risk factors might benefit most from RSV prevention interventions. Not applicable, this is not a clinical trial.


  • Open Access

    Risk Factors for Severe COVID‐19 Among Children and Adolescents Enrolled in Acute Respiratory Infection Sentinel Surveillance in South Africa, 2020–2022

    by Kate Bishop, Susan Meiring, Stefano Tempia, Anne von Gottberg, Nicole Wolter, Jackie Kleynhans, Fahima Moosa, Mignon du Plessis, Jocelyn Moyes, Mvuyo Makhasi, et al.

    Background: Identifying children at risk for severe COVID‐19 disease from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) may guide future mitigation interventions. Using sentinel surveillance data, we aimed to identify risk factors for SARS‐CoV‐2–associated hospitalisation among patients aged ≤ 18 years with respiratory illness.Methods: From April 2020 to March 2022, patients meeting study case definitions were enrolled at four outpatient influenza‐like illness (ILI) and five inpatient severe respiratory infection (SRI) surveillance sites and tested for SARS‐CoV‐2 infection using polymerase chain reaction (PCR). Each ILI clinic shared a catchment area with its corresponding SRI hospital. Potential risk factors for SARS‐CoV‐2–associated hospitalisation were analysed using multivariable logistic regression by comparing inpatient versus outpatient SARS‐CoV‐2 cases.Results: Of 4688 participants aged ≤ 18 years, 4556 (97%) with complete PCR and HIV data were included in the analysis. Among patients with ILI and SRI, 92/1145 (8%) and 154/3411 (5%) tested SARS‐CoV‐2 positive, respectively. Compared to outpatients, hospitalised SARS‐CoV‐2 cases were associated with age < 6 months ([adjusted odds ratio (aOR) 8.0, 95% confidence interval (CI) 2.7–24.0] versus 1–4 years); underlying medical condition other than HIV [aOR 5.8, 95% CI 2.3–14.6]; laboratory‐confirmed Omicron BA.1/BA.2 or Delta variant ([aOR 4.9, 95% CI 1.7–14.2] or [aOR 2.8, 95% CI 1.1–7.3] compared to ancestral SARS‐CoV‐2); and respiratory syncytial virus coinfection [aOR 6.2, 95% CI 1.0–38.5].Conclusion: Aligning with previous research, we identified age < 6 months or having an underlying condition as risk factors for SARS‐CoV‐2–associated SRI hospitalisation and demonstrated the potential of sentinel surveillance to monitor COVID‐19 in children.


  • Open Access

    Home-based testing as an approach to estimate influenza vaccine effectiveness in South Africa, 2022 -- a pilot study

    by Jocelyn Moyes, Mvuyo Makhasi, Sibongile Walaza, Ntombela P, Fahima Moosa, Anne von Gottberg, Nicole Wolter, Mignon du Plessis, Hunt G, Cawood C, et al.

    Background. Surveillance programmes for influenza and other respiratory pathogens are important to generate vaccine effectiveness (VE) estimates and to inform vaccine composition. We aimed to explore the feasibility and acceptability of home-based testing. Methods In 3/9 provinces in South Africa, we established a self-referral system for individuals aged ≥18 years with respiratory symptoms of ≤10 days duration. Following electronic consent, swab collection material was delivered to participants who also completed a questionnaire including self-reported vaccination status. Swabs were tested by PCR for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. A test negative methodology was used to estimate influenza VE. Results Of 1456 samples collected between 1 December 2021 and 31 August 2022, 73 (5%) tested positive for influenza, 38 (3%) tested positive for RSV and 394 (27%) for SARS-CoV-2. We subtyped 55% (40/73) of the influenza positive specimens; 16/40 (40%) were influenza A (A(H1N1)pdm09; 10/40 (25%)A (H3N2)) and all 14/40(35%) influenza B were B/Victoria. Only 20% (279/1451) of participants reported influenza-like illness case definition symptoms of fever and cough. Influenza vaccine coverage was 11% (157/1454). The overall influenza VE was 26% (95% confidence interval, -73%;69%). Of the completed acceptability questionnaires, 123/127 (97%) participants would make use of the service again. 36% (46/127) of enrolled participants were recruited through the testing centre’s webpage and 13% (17/127) through social media. Conclusions Home-based swabbing was feasible and acceptable. We were able to calculate an influenza VE, although a large sample size and verification of vaccine status may improve the VE estimate in the future.

  • Open Access

    Healthcare utilization during the first two waves of the COVID-19 epidemic in South Africa: A cross-sectional household survey

    by Nicole Wolter, Stefano Tempia, Anne von Gottberg, Jinal N Bhiman, Sibongile Walaza, Jackie Kleynhans, Jocelyn Moyes, Sue Aitken, Sarah Magni, Jessica Yun, et al.

    Healthcare utilization surveys contextualize facility-based surveillance data for burden estimates. We describe healthcare utilization in the catchment areas for sentinel site healthcare facilities during the first year of the COVID-19 pandemic. We conducted a cross-sectional healthcare utilization survey in households in three communities from three provinces (KwaZulu-Natal, Western Cape and North West). Field workers administered structured questionnaires electronically with the household members reporting influenza-like illness (ILI) in the past 30 days or severe respiratory illness (SRI) since March 2020. Multivariable logistic regression was used to identify factors associated with healthcare utilization among individuals that reported illness. From November 2020 through April 2021, we enrolled 5804 households and 23,003 individuals. Any respiratory illness was reported by 1.6% of individuals; 0.7% reported ILI only, 0.8% reported SRI only, and 0.1% reported both ILI and SRI. Any form of medical care was sought by 40.8% (95% CI 32.9% - 49.6%) and 71.3% (95% CI 63.2% - 78.6%) of individuals with ILI and SRI, respectively. On multivariable analysis, respiratory illness was more likely to be medically attended for individuals at the Pietermaritzburg site (aOR 3.2, 95% CI 1.1–9.5, compared to Klerksdorp), that were underweight (aOR 11.5, 95% CI 1.5–90.2, compared to normal weight), with underlying illness (aOR 3.2, 95%CI 1.2–8.5), that experienced severe illness (aOR 4.8, 95% CI 1.6–14.3) and those with symptom duration of ≥10 days (aOR 7.9, 95% CI 2.1–30.2, compared to <5 days). Less than half of ILI episodes and only 71% of SRI episodes were medically attended during the first two COVID-19 waves in South Africa. Facility-based data may underestimate disease burden during the COVID-19 pandemic.